Early detection of Alzheimer's disease (AD) raises a number of challenging legal questions. In this essay, we explore some of those questions, such as: Is a neurological indicator of increased risk for AD a legally relevant brain state before there are any outward behavioral manifestations? How should courts address evidentiary challenges to the admissibility of AD-related neuroimaging? How should the government regulate the marketing of neuroimaging diagnostic tools? How should insurance coverage for the use of these new tools be optimized? We suggest that many voices and multidisciplinary perspectives are needed to answer these questions and ensure that legal responses are swift, efficient, and equitable.
Preston, J., McTeigue, J., Opperman, C., Scott Krieg, J. D., Brandt-Fontaine, M., Yasis, A., & Shen, F. X. (2016). The legal implications of detecting Alzheimer’s disease earlier. AMA Journal of Ethics, 18(12), 1207–1217. https://doi.org/10.1001/journalofethics.2016.18.12.hlaw1-1612